Serum Procalcitonin Levels Predict Mortality Risk in Patients With Pulmonary Tuberculosis: A Single-Center Prospective Observational Study.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
13 10 2020
Historique:
received: 12 12 2019
accepted: 18 05 2020
pubmed: 24 5 2020
medline: 12 3 2021
entrez: 24 5 2020
Statut: ppublish

Résumé

Globally, tuberculosis is the leading infectious cause of death; discovering biomarkers that predict a high mortality risk may improve treatment outcomes. We prospectively enrolled 252 pulmonary tuberculosis patients who were not coinfected with human immunodeficiency virus and initiated antituberculosis treatment, measured serum procalcitonin levels (PCT), and assessed mortality risk. PCT serum levels higher than 0.13 (day 0), 0.05 (day 7), 0.12 (day 14), or 0.06 (day 28) ng/mL predicted nonsurvivors with odds ratios of 7.9, 14.3, 20.0, and 7.3, respectively (P ≤ .005 for all), respectively. Therefore, serum PCT levels are a promising mortality risk indicator for patients with pulmonary tuberculosis. Main Point. For patients with pulmonary tuberculosis, a promising mortality risk indicator is the level of serum procalcitonin, which is weakly associated with sputum bacterial load and independent of radiographic findings.

Identifiants

pubmed: 32445568
pii: 5843442
doi: 10.1093/infdis/jiaa275
doi:

Substances chimiques

Biomarkers 0
Procalcitonin 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1651-1654

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Takeshi Osawa (T)

Department of Respiratory Medicine, Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan.

Masato Watanabe (M)

Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Kozo Morimoto (K)

Department of Respiratory Medicine, Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan.
Division of Clinical Research, Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan.

Masao Okumura (M)

Department of Respiratory Medicine, Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan.

Takashi Yoshiyama (T)

Department of Respiratory Medicine, Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan.
Research institute of tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Hideo Ogata (H)

Department of Respiratory Medicine, Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan.

Hajime Goto (H)

Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Shoji Kudoh (S)

Department of Respiratory Medicine, Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan.

Ken Ohta (K)

Department of Respiratory Medicine, Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan.

Yuka Sasaki (Y)

Department of Respiratory Medicine, Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH